New PAH Treatment System Submitted for FDA Approval
Trevyent®, a new treatment system that utilizes subcutaneous delivery of treprostinil for pulmonary arterial hypertension (PAH) patients, was submitted to the U.S. Food & Drug Administration (FDA) for approval. The FDA received a New Drug Application (NDA) by United Therapeutics Corporation in September for Trevyent, a disposable pump and skin patch system or PatchPump® that